Alzheimer Disease Vaccine

14,000,000 Leading Edge Experts on the ideXlab platform

Scan Science and Technology

Contact Leading Edge Experts & Companies

Scan Science and Technology

Contact Leading Edge Experts & Companies

The Experts below are selected from a list of 645 Experts worldwide ranked by ideXlab platform

Paula Bickford - One of the best experts on this subject based on the ideXlab platform.

  • The Promise and Perils of an Alzheimer Disease Vaccine: A Video Debate
    Journal of Neuroimmune Pharmacology, 2009
    Co-Authors: Dave Morgan, Gary Landreth, Paula Bickford
    Abstract:

    Alzheimer’s Disease (AD) is a critical health care problem that has considerable social and economic impact on society. Effective treatments have been elusive. One major causal factor for the Disease is believed to be the deposition of amyloid fibrils in the brain, which ultimately leads to neurodegeneration and cognitive dysfunction. Based on the amyloid hypothesis of Alzheimer’s Disease, many therapies presently target the amyloid beta (Aβ) peptide, the monomeric protein fragment that assembles to form fibrils. This video article takes the form of a debate between Dr. Morgan and Dr. Landreth on the merits and drawbacks of an Alzheimer’s Disease Vaccine. Click on Supplemental Material to watch the streaming video.

Dave Morgan - One of the best experts on this subject based on the ideXlab platform.

  • The Promise and Perils of an Alzheimer Disease Vaccine: A Video Debate
    Journal of Neuroimmune Pharmacology, 2009
    Co-Authors: Dave Morgan, Gary Landreth, Paula Bickford
    Abstract:

    Alzheimer’s Disease (AD) is a critical health care problem that has considerable social and economic impact on society. Effective treatments have been elusive. One major causal factor for the Disease is believed to be the deposition of amyloid fibrils in the brain, which ultimately leads to neurodegeneration and cognitive dysfunction. Based on the amyloid hypothesis of Alzheimer’s Disease, many therapies presently target the amyloid beta (Aβ) peptide, the monomeric protein fragment that assembles to form fibrils. This video article takes the form of a debate between Dr. Morgan and Dr. Landreth on the merits and drawbacks of an Alzheimer’s Disease Vaccine. Click on Supplemental Material to watch the streaming video.

Gary Landreth - One of the best experts on this subject based on the ideXlab platform.

  • The Promise and Perils of an Alzheimer Disease Vaccine: A Video Debate
    Journal of Neuroimmune Pharmacology, 2009
    Co-Authors: Dave Morgan, Gary Landreth, Paula Bickford
    Abstract:

    Alzheimer’s Disease (AD) is a critical health care problem that has considerable social and economic impact on society. Effective treatments have been elusive. One major causal factor for the Disease is believed to be the deposition of amyloid fibrils in the brain, which ultimately leads to neurodegeneration and cognitive dysfunction. Based on the amyloid hypothesis of Alzheimer’s Disease, many therapies presently target the amyloid beta (Aβ) peptide, the monomeric protein fragment that assembles to form fibrils. This video article takes the form of a debate between Dr. Morgan and Dr. Landreth on the merits and drawbacks of an Alzheimer’s Disease Vaccine. Click on Supplemental Material to watch the streaming video.

Christian Haass - One of the best experts on this subject based on the ideXlab platform.

  • New hope for Alzheimer Disease Vaccine
    Nature Medicine, 2002
    Co-Authors: Christian Haass
    Abstract:

    Clinical trials of a Vaccine against Alzheimer Disease came to an abrupt halt this year when several patients developed inflammation in the brain. Now, the first data from the trial and a mouse study brighten the outlook for this spectacular and simple treatment approach ( pages 1263–1269 and 1270–1275 ).

Wu Yong-ge - One of the best experts on this subject based on the ideXlab platform.

  • Construction of Prokaryotic Expression Vector for Therapeutic Alzheimer Disease Vaccine
    Chinese Journal of Biologicals, 2007
    Co-Authors: Wu Yong-ge
    Abstract:

    Objective To construct a prokaryotic expression vector for therapeutic Alzheimer Disease(AD) Vaccine.MethodsLigating the DNA sequence encoding β-amyloid protein(Aβ) 1-15 to that encoding murine chemotactic factor BCA-1 by PCR to obtain synthetic gene AZM.Insert AZM gene into genetically modified prokaryotic expression vector pRSET/no His and identify the recombinant plasmid pREST-AZM by restriction analysis and DNA sequencing.Results Both restriction analysis and DNA sequencing proved that AZM gene was correctly inserted into expression vector pREST/no His.Conclusion The prokaryotic expression vector of Aβ42 subunit Vaccine was successfully constructed.